Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20539536 | 1.00 | PTGER4 (0.51) | PTGER4PTGER2NR1H4 | |
| SCHEMBL18740120 | 0.95 | PTGER4 (0.49) | PTGER4PTGER2NR1H4 | |
| SCHEMBL18740123 | 0.95 | PTGER4 (0.49) | PTGER4PTGER2NR1H4 | |
| SCHEMBL18740241 | 0.92 | PTGER4 (0.51) | PTGER4PTGER2 | |
| SCHEMBL18740243 | 0.92 | PTGER4 (0.51) | PTGER4PTGER2 | |
| SCHEMBL18758566 | 0.91 | PTGER4 (0.42) | PTGER4PTGER2 | |
| SCHEMBL28922411 | 0.91 | PTGER4 (0.42) | PTGER4PTGER2 | |
| SCHEMBL18740052 | 0.90 | PTGER4 (0.53) | PTGER4PTGER2 | |
| SCHEMBL18740050 | 0.90 | PTGER4 (0.53) | PTGER4PTGER2 | |
| SCHEMBL20539130 | 0.87 | PTGER4 (0.51) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434246-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-09-06 | — | — | US | claimed |
| EP-3362454-B1 | EP4 ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2021-12-08 | — | — | EP | claimed |
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | claimed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | claimed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | claimed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | claimed |
| US-11434246-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-09-06 | — | — | US | disclosed |
| EP-3362454-B1 | EP4 ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2021-12-08 | — | — | EP | disclosed |
| EP-3362454-B1 | EP4 ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| CN-108473497-B | EP4 antagonists | 卫材R&D 管理有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20180305362-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-25 | — | — | US | disclosed |
| WO-2017066633-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434246-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885NR1H4 141/4885 |
| US-20180305362-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885NR1H4 141/4885 |
| US-10316040-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885NR1H4 141/4885 |
| US-10941148-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885NR1H4 141/4885 |
| US-20190315754-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885NR1H4 141/4885 |
| US-20210347779-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885NR1H4 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.